Last Thursday, Extendicare reported its fourth quarter and fiscal 2015 results. In the fourth quarter, the company earned $34.3-million in revenue of $270.8-million. The company’s bottom line number was a 17 per cent improvement over the $29.3-million it posted in the same period a year prior.
“We continue to execute on our Canadian-focused strategy to grow across the continuum of seniors care and services,” said CEO Tim Lukenda. “We are pleased with our progress in building AFFO through the strategic deployment of proceeds from the sale of our U.S. operations. We expect continued growth across all segments of our business as we integrate our recent acquisitions and build off the strong platform we have established. We are firmly focused on building shareholder value over the long term,” Mr. Lukenda added.
Loe says the quarter was more evidence of Extendicare’s stability.
“Our investment thesis on EXE is unchanged and at its core, assumes that Extendicare’s nursing care/homecare/assisted living operations can adequately fund existing dividend policy ($0.48/shr annually) and with further operating income anticipated from assisted living occupancy expansion, we believe current dividend yield of 5.4% represents fair value for new investors,” he said. “Management projects AFFO contribution from newly acquired operations of $0.20/shr, $0.10/shr of which we assume is still expected from Revera Home Health as guided previously, and our projections are consistent with this expectation.”
In a research update to clients today, Loe maintained his “Buy” rating and one-year price target of $10.50 on Extendicare, implying a return of 17.3 per cent at the time of publication (22.7 per cent including dividend yield).
It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]
Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]
Following a widely applauded first quarter beat, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Alphabet (Alphabet… [Read More]
Following an acquisition, Echelon Capital Markets analyst Stefan Quenneville has maintained his "Buy" rating on Nova Leap Health (Nova Leap… [Read More]
The stock has been flat since November, but Citi analyst Tyler Radke thinks there is now money to be made… [Read More]
Following the company's fourth quarter results, Eight Capital analyst Kiran Sritharan has maintained his "Buy" rating on Sabio Holdings (Sabio… [Read More]